min-117 min-117 min-117 (known formerly as wf-516) is an investigational antidepressant which is under development by minerva neurosciences for the clinical treatment of major depressive disorder (mdd). it is described as a 5-ht1a and 5-ht2a receptor antagonist and inhibitor of serotonin and dopamine reuptake, and is also reported to possess affinity for the α1a- and α1b-adrenergic receptors. as of may 2015, min-117 is in phase ii clinical trials for mdd. in december 2019, minerva announced that min-117 was no longer in clinical development for mdd after disappointing results in a phase iib trial. min-117clinical dataother nameswf-516identifiers iupac name (2s)-1--3-furan-4-yloxy]propan-2-ol cas number310392-94-0pubchem cid9806065chemspider7981825uniiqm05g7nm4hchemical and physical dataformulac25h25cl2n3omolar mass454.40 g·mol−13d model (jsmol)interactive image smiles cc1=nn=c(o1)c2=cc3=c(o2)c=cc=c3oc(cn4ccc(cc4)c5=cc(=c(c=c5)cl)cl)o inchi inchi=1s/c25h25cl2n3o4/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17/h2-6,11-12,16,18,31h,7-10,13-14h2,1h3/t18-/m0/s1key:xiydiplatgrhec-sfhvurjksa-n